Epithalon

Epithalon (also rendered as Epitalon or Epithalone) is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG). It was developed by the St. Petersburg Institute of Bioregulation and Gerontology in Russia, where researcher Vladimir Khavinson and colleagues synthesized it based on the active components of epithalamin, a polypeptide extract from the bovine pineal gland. The pineal gland is the body's principal source of melatonin and plays a central role in circadian regulation and aging.

The most studied mechanism of Epithalon's action involves telomerase activation. Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division; critically short telomeres trigger cell senescence or apoptosis, contributing to tissue aging. Research published in the Bulletin of Experimental Biology and Medicine found that adding Epithalon to cultures of telomerase-negative human fetal fibroblasts induced expression of hTERT (the catalytic subunit of telomerase), enzymatic telomerase activity, and measurable telomere elongation ^[1].

Human clinical research, while limited in scale, has produced some notable results. Studies conducted on patients aged 60-65 and 75-80 found that both epithalamin and Epithalon significantly increased telomere lengths in blood cells compared to controls ^[3]. A clinical trial in retinitis pigmentosa patients found that Epithalon produced a positive clinical effect in 90% of treated subjects. Additional research suggests antioxidant, neuroprotective, and antimutagenic effects, as well as modulation of neuroendocrine function including melatonin synthesis.

The research base for Epithalon spans over 25 years and includes in vitro, in vivo, and in silico methods. However, the vast majority of primary studies come from a single Russian research group, and independent replication in Western academic institutions remains sparse. The peptide is not approved by any major regulatory body and is sold strictly as a research compound.